Incidence of Thiopurine-Induced Severe Myelosuppression in a Nationwide Cohort of Patients With Inflammatory Bowel Disease.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 39436267.
- Also identified by DOI 10.14309/ajg.0000000000003141 and PMC identifier 11864046.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
There is paucity of data on the incidence of severe thiopurine (TP)-induced myelosuppression (TIM) among patients with inflammatory bowel disease (IBD). Using the Veterans Affairs Healthcare System, we identified patients with IBD with normal pretreatment TP S-methyltransferase levels who received TPs for 6 months and developed severe TIM. Among 73,392 patients with IBD, 14,760 had received TPs, and 2,823 had a normal TP S-methyltransferase level. The incidence rate of severe TIM was 1.25 per 1,000 patient-years. The incidence of severe TIM was very low, calling into question the necessity of frequent long-term complete blood count monitoring among patients with IBD on TPs.
Medical subject headings
- Inflammatory Bowel Diseases
- Azathioprine
- Mercaptopurine
- Immunosuppressive Agents